Skip to content

    Sakar Healthcare Limited

    SAKAR
    Healthcare·11 Nov 2025
    Management Summary

    Sakar Healthcare reported strong H1 FY26 results with revenue growing 31.4% YoY to ₹110.30 crores, driven by a significant increase in oncology segment contribution. While Q2 EBITDA margins saw a temporary dip to 20% due to one-time expenses, management reaffirmed its FY26 revenue target of ₹280 crores and expects margins to recover. The company is progressing with European marketing authorizations and aims for substantial growth in oncology exports.

    Highlights

    5

    • Revenue from operations for H1 FY26 increased by 31.4% YoY to ₹110.30 crores.

    • PAT for H1 FY26 grew by 27.8% YoY to ₹9.21 crores.

    • Oncology contribution to total revenue nearly doubled to 37% in H1 FY26 from 19% last year.

    • Working capital cycle reduced by 30 days to 135 days as of September 2025.

    • EU GMP approved oncology facility at Bavla is vertically integrated from API to finished dosage form.

    Concerns

    2

    • EBITDA margin for Q2 FY26 declined to 20% from 27% in Q2 FY25, primarily due to one-time operating leverage impact from newly commissioned oncology lines and increased business development expenses.

    • PAT for Q2 FY26 decreased by 5.35% YoY to ₹4.54 crores.

    Key financials

    Metrics

    15

    Periods

    3

    Headline

    4
    • Total Assets (Sep 2025)
      ₹448.6 Cr
    • Net Worth (Sep 2025)
      ₹303.25 Cr
    • Debt-to-Equity Ratio
      0.38 ratio
    • Working Capital Cycle (Sep 2025)
      135 days

    Q2 FY26

    4
    • Revenue
      ₹57.56 Cr
      YoY+34.6%QoQ+9.1%
    • EBITDA
      ₹11.35 Cr
      YoY-1.3%
    • EBITDA Margin
      20%
    • PAT
      ₹4.54 Cr
      YoY-5.4%

    H1 FY26

    7
    • Revenue
      ₹110.3 Cr
      YoY+31.4%
    • EBITDA
      ₹24.06 Cr
      YoY+8.4%
    • EBITDA Margin
      22%
    • PAT
      ₹9.21 Cr
      YoY+27.8%
    • Gross Margins
      46%

    Capital allocation

    2
    high confidence
    CategoryHeadline
    Capex

    Capex disclosed

    Debt

    Debt disclosed

    Guidance & targets

    6
    CategoryTargetPriority
    Revenue
    Revenue
    ₹280 crores
    		High
    Margin
    EBITDA Margin
    25%
    		High
    Oncology Export Potential
    Revenue from existing agreements
    >₹450 crores
    		Medium
    Export Sales Growth
    Export sales growth
    Double FY26 export sales (50%+ overall growth)
    		Medium
    Marketing Authorizations
    Marketing authorizations received
    100
    		Medium
    Oncology Revenue Potential
    Revenue from oncology plant at full capacity
    ₹1,000 crores
    		Medium

    Commercialization of first European MAs

    Q4 FY26
    CurrentMAs received, logistics/artwork being finalized for Bulgaria
    TargetFirst product launched/exported to Bulgaria

    Why it matters

    First revenue realization from new European market authorizations, validating the company's strategic shift.

    we are expecting quarter four of this financial year to capture this export to Bulgaria.

    How to verify

    key_financials.metrics[label='Revenue (Q4 FY26)']

    Risks & concerns

    1
    RiskSeverity

    EBITDA margin compression in Q2 FY26

    Q2 FY26 EBITDA margin declined to 20% from 27% in Q2 FY25, attributed to one-time expenses like increased business development travel and product registration filing fees. Management expects recovery from Q3 FY26. — Analyst acknowledged

    medium

    Q&A highlights

    8

    “The country is Bulgaria, where we have received one-by-one as on date five marketing authorizations and one from Bosnia. So, total count is six basically from Europe as on date... we are expecting quarter four of this financial year to capture this export to Bulgaria.”

    Clarifies specific countries and products for initial MA approvals and provides a timeline for the first commercial launch in Europe.

    asked by Ankit Gupta

    2 min read6 chapters

    Detailed Narrative

    01

    Oncology-Focused Transformation and EU GMP Approval

    Sakar Healthcare is transitioning into a research-driven oncology-focused pharmaceutical organization, founded in 2004. The company operates with WHO GMP and EU GMP approved facilities in Gujarat, catering to over 60 countries. Its vertically integrated oncology plant at Bavla has received EU GMP approval for both oral and injection manufacturing blocks, enabling pathways to regulated markets.

    02

    Robust Financial Performance in Q2 & H1 FY26

    For H1 FY26, revenue from operations grew by 31.4% YoY to ₹110.30 crores, with Q2 FY26 revenue at ₹57.56 crores, up 34.6% YoY. PAT for H1 FY26 increased by 27.8% YoY to ₹9.21 crores. Gross margins remained healthy at 46%, supported by operational efficiency and a richer product mix, despite a temporary dip in Q2 EBITDA margin to 20% due to one-time📎 expenses.

    03

    Strategic Business Model and Global Market Expansion

    The company's strategic business model includes CDMO-CMO services, own-brand export, and contract development. Own-brand export now contributes over 70% of total revenues, improving profitability across APAC, Latin America, Africa, CIS, and Europe. Sakar Healthcare serves as a trusted partner for leading pharmaceutical companies like Zydus Life Sciences and Torrent Pharmaceuticals.

    04

    Advancements in Oncology Product Development and Registrations

    Sakar has developed 55 oncology products in-house, with 32 CTD dossiers ready for registration. To date, 80 dossiers have been submitted worldwide, and 11 registrations or marketing authorizations have been granted, including six in Europe (Bulgaria, Bosnia) and the rest in APAC and Latin America. The first commercial launch in Bulgaria is expected in Q4 FY26, with products like docetaxel, irinotecan, carboplatin, gemcitabine, and tamoxifen.

    05

    Operational Efficiency and R&D Investment

    The company's working capital cycle improved significantly, reducing by 30 days from 165 days in March 2025 to 135 days in September 2025, driven by efficiency in stock management. H1 FY26 R&D expenses amounted to ₹3 crores, with management emphasizing that the ₹27 crores capex for the oncology plant is largely complete, with only maintenance capex expected for FY27.

    06

    Future Growth Outlook and Long-term Vision

    Sakar Healthcare aims to achieve ₹280 crores in revenue with a 25% EBITDA margin for FY26. The company anticipates export sales to double in FY27, contributing to over 50% overall growth. Long-term, the oncology plant is projected to generate ₹1,000 crores in revenue by FY30, supported by 250-300 full-fledged marketing authorizations. The current infrastructure is deemed sufficient to support this growth without further significant capex.

    This is an AI-generated summary of a publicly available earnings call transcript. It is for informational purposes only and does not constitute investment advice, a recommendation, or an endorsement. inve.money is not a SEBI-registered investment advisor. Please consult a qualified financial advisor before making any investment decisions.